Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Loses Glivec Case, May Not Move SC (India)

This article was originally published in PharmAsia News

Executive Summary

The Madras High Court has dismissed the petition filed by Swiss pharmaceutical major Novartis against the validity of a specific clause - 3(d) - in the Indian Patents Act that restricted patenting of minor improvements of known molecules. Dismissing the petition, which said that 3 (d) violated the TRIPS (Trade-Related Aspects of Intellectual Property Rights) agreement and provided "unguided power" to patent controllers to reject applications for patents on the ground that they are not inventions, the court advised Novartis to approach the dispute settlement forum of the World Trade Organization on TRIPS-related complaints. Novartis went to court in February 2006 after its patent application on Glivec, a cancer drug, was rejected by the Patent Office due to the provisions disallowing patenting of minor improvements in known molecules or derivative of a known substance unless they differ significantly in properties with regard to efficacy. "We disagree with this ruling. We, however, may not appeal to the Supreme Court. We are awaiting the full decision to better understand the Court's position. Our actions advanced this essential debate in India - now local and international leaders in both industry and academia recognize the inadequacies of Section 3(d) and are raising serious concerns about the deficiencies of the Indian patent system," Ranjit Shahani, vice-chairman and managing director, Novartis India said. (Click here for more

You may also be interested in...



WHO Prequalifies Celltrion’s Rituximab

Celltrion's Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the World Health Organization.

Medac Will Market Fresenius Kabi’s Adalimumab In Germany

Fresenius Kabi’s Idacio biosimilar adalimumab rival to Humira will from the start of June be marketed in Germany by Medac, following a deal between the two companies.

Coronavirus Update: Roche Launches Remdesivir Plus Actemra Trial, GSK Plans 1bn Vaccine Adjuvant Doses

Roche is teaming up with Gilead on the combination trial, aiming to improve on results of remdesivir alone, which has failed to show mortality benefits in COVID-19 patients.

UsernamePublicRestriction

Register

LL1132466

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel